Simultaneous macroamylasemia and macrolipasemia in a patient with systemic lupus erythematosus in remission.
We report the fourth case of simultaneous macroamylasemia and macrolipasemia. A 39-year-old woman had been treated for systemic lupus erythematosus from 1982 to 1993. She was found to have an unexplained increase in serum amylase and lipase activities since 1996. Immunoprecipitation assay showed that amylase was bound to IgA2-kappa and IgA1-kappa (IgA2 > IgA1), whereas lipase was bound to IgA1-kappa. During a follow-up period up to December 1999, the patient did not develop any additional autoimmune or lymphoproliferative disorders. In the situation of atypical clinical features associated with hyperamylasemia and hyperlipasemia, the possibility of macroenzymes should be considered.
Goto
H
H
Third Department of Internal Medicine, Akita University School of Medicine.
Wakui
H
H
Komatsuda
A
A
Imai
H
H
Miura
A B
AB
Fujita
K
K
D000328:Adult; D000681:Amylases / Q000097:blood*; D000918:Antibody Specificity; D000936:Antigen-Antibody Complex / Q000097:blood*; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D001324:Autoantigens / Q000097:blood* / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000201:enzymology* / Q000276:immunology; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood* / Q000276:immunology; D007145:Immunoglobulin kappa-Chains / Q000097:blood*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008049:Lipase / Q000097:blood*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000201:enzymology* / Q000276:immunology; D008970:Molecular Weight; D011239:Prednisolone / Q000627:therapeutic use; D011485:Protein Binding; D012074:Remission Induction
D000936:Antigen-Antibody Complex; D001323:Autoantibodies; D001324:Autoantigens; D007070:Immunoglobulin A; D007145:Immunoglobulin kappa-Chains; D007166:Immunosuppressive Agents; D011239:Prednisolone; D008049:Lipase; D000681:Amylases